文献速递淋巴瘤

晚期经典型霍奇金淋巴瘤新Deauville评分5a的预后验证

Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

研究在德国霍奇金研究组随机3期试验(HD18和HD21)中验证新提出的Deauville评分5a(DS5a)对晚期经典型霍奇金淋巴瘤(AS-cHL) interim PET(PET-2)的预后区分能力。主要分析队列为HD18修正后标准臂(统一接受6周期eBEACOPP),敏感队列包括HD18意向治疗人群及HD21的eBEACOPP和BrECADD臂。结果显示DS5a发生率低(各队列4%-6%),且与DS1-4相比仍提示不良无进展生存(PFS),支持其识别小部分高危患者。

要点

  • DS5a在AS-cHL中发生率低(4%-6%),但PFS仍显著劣于DS1-4(HR 2.57-5.47)。
  • 新定义下DS4与DS1-3未一致分离,可能受PET适应治疗影响。
  • DS5a有助于识别小部分高危患者,支持采用PET定量生物标志物进行风险适应。

核心结论

  • 新提出的DS5a可识别一小部分高危AS-cHL患者,其PFS较DS1-4仍差。

研究设计与样本

  • 基于德国霍奇金研究组HD18和HD21随机3期试验的回顾性分析。
  • 主要分析队列为HD18修正后标准臂(统一6周期eBEACOPP),共639例。
  • 敏感队列包括HD18意向治疗人群(1745例)及HD21的eBEACOPP臂(568例)和BrECADD臂(560例)。
  • 采用从PET-2开始的landmark Cox模型分析PFS。

主要发现

  • DS5a发生率在各队列为4%-6%(39/639、67/1745、33/568、29/560)。
  • 主要队列中,DS5与DS1-3相比PFS更差(HR 3.00;95%CI 1.25-7.23),与DS1-4相比亦差(HR 2.35;95%CI 1.01-5.50)。
  • 敏感队列中,DS5a与DS1-4相比HR范围为2.57-5.47。
  • 新定义下DS4与DS1-3未一致分离,可能因PET适应治疗影响。
  • 总生存趋势一致,但事件数少限制解读。

关键数值与推荐

  • DS5a定义为摄取值>2倍肝脏本底且无新病灶;DS5b定义为出现新病灶。
  • DS5a在各队列发生率4%-6%。
  • 主要队列DS5 vs DS1-3的PFS HR为3.00(95%CI 1.25-7.23)。
  • 主要队列DS5 vs DS1-4的PFS HR为2.35(95%CI 1.01-5.50)。
  • 敏感队列DS5a vs DS1-4的HR范围为2.57-5.47。

临床怎么用

  • 对于AS-cHL患者,PET-2评估为DS5a提示高危,可考虑加强风险适应治疗。
  • DS5a发生率低,需结合定量PET生物标志物进一步优化风险分层。

局限性

  • 总生存事件数少,限制OS解读。
  • 敏感队列中DS4与DS1-3未一致分离,可能受PET适应治疗影响。
  • 研究为回顾性分析,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Lugano Imaging Committee recently refined the Deauville score (DS), subdividing DS5 into DS5a (>2× liver uptake without new lesions) and DS5b (new lesions). We investigated whether this improves prognostic discrimination at interim positron emission tomography (PET) after 2 cycles (PET-2) in patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) treated in recent German Hodgkin Study Group randomized phase 3 trials. The primary analysis cohort was HD18 postamendment standard arms (uniform treatment with 6 cycles of escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [eBEACOPP]); sensitivity cohorts were HD18 intention-to-treat and HD21 eBEACOPP and brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone arms. Progression-free survival (PFS) was analyzed by landmark Cox models starting at PET-2. DS5a was infrequent (4%-6% across cohorts; 39/639, 67/1745, 33/568, and 29/560). In the primary cohort, DS5 was associated with inferior PFS vs DS1 to DS3 (hazard ratio [HR], 3.00; 95% confidence interval [CI], 1.25-7.23) and vs DS1 to DS4 (HR, 2.35; 95% CI, 1.01-5.50). Across sensitivity cohorts, DS5a remained adverse compared with DS1 to DS4 (HR range, 2.57-5.47), whereas DS4 according to the new definition did not consistently separate from DS1 to DS3, which is likely a result of PET-adapted treatment. Overall survival trends were concordant, but interpretation is limited by few events. To our knowledge, this is the first prognostic validation of the refined DS in prospectively randomized trial populations. The newly introduced DS5a isolates a small high-risk AS-cHL, which further supports risk assessment and adaptation using quantitative biomarkers from PET. The HD18 and HD21 trials were registered at www.clinicaltrials.gov as NCT00515554 and NCT02661503, respectively.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Leiders S, Ufton D, Kaul H, et al. Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma. Blood Adv. 2026. PMID: 42379221. doi:10.1182/bloodadvances.2026019712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。